Effect of Local Anesthetic EMLA (Lidocaine 2.5% and Prilocaine 2.5%) Cream and Reduction in Dose, Pain and Intravenous Analgesic During Permanent Pacemaker Implantation

Hillel Yaffe Medical Center

Status: Unknown

Conditions: Pacemaker Implantation; Pain

Treatments: Drug: Dormicum 2.5 mg and Pethidine 25 mg; Drug: EMLA Analgesic Cream

Study type: Interventional

Funder types: Other

Identifiers

NCT02016976

0094-13-HYMC

Details and patient eligibility

About

The investigators believe that the local anesthetic EMLA (Lidocaine 2.5% and Prilocaine 2.5%) cream will lessen pain and reduce the need for anesthesia and analgesia, when implanting a permanent pacemaker.

Enrollment: 40 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients undergoing pacemaker implantation

Exclusion criteria

• Dementia Patients
• Psychiatric Patients
• Unconscious Patients
• Patients with sensitivity to EMLA

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

40 participants in 2 patient groups

EMLA analgesic cream

Active Comparator group

Description:

Patients who have had EMLA analgesic cream applied to area before pacemaker implantation

Treatment:

Drug: EMLA Analgesic Cream

Routine treatment

Active Comparator group

Description:

Patients who have received routine treatment (Dormicum 2.5 mg and Pethidine 25 mg) before and during pacemaker implantation

Treatment:

Drug: Dormicum 2.5 mg and Pethidine 25 mg